Research advances in the treatment of primary biliary cirrhosis
10.3969/j.issn.1001-5256.2022.09.035
- VernacularTitle:原发性胆汁性胆管炎的治疗进展
- Author:
Xing LYU
1
;
Ting LI
1
;
Xiaodong SUN
1
;
Jianpeng ZHOU
1
;
Dongxia WANG
1
;
Guoyue LYU
1
Author Information
1. First Department of Hepatopancreatobiliary Surgery, The First Hospital of Jilin University, Changchun 130021, China
- Publication Type:Reviews
- Keywords:
Primary Biliary Cholangitis;
Drug Therapy;
Liver Transplantation
- From:
Journal of Clinical Hepatology
2022;38(9):2130-2135
- CountryChina
- Language:Chinese
-
Abstract:
Primary biliary cholangitis (PBC) is an autoimmune disease commonly observed in middle-aged women, and it may progress to liver cirrhosis and liver failure. Ursodeoxycholic acid and obeticholic acid are the only first - and second-line drugs approved by the FDA, but about 40% of patients are insensitive to UDCA. Studies are being conducted on a variety of second-line drugs such as fibrates and immunosuppressive drugs, and liver transplantation is the only treatment method for end-stage PBC. This article reviews the research advances in the treatment of PBC and related mechanisms, in order to provide a reference for clinical practice.
